Clinician Input Template for CADTH pan-Canadian Oncology Drug Review Program

*Before completing this template, be sure to* [*register*](https://drugreviewsadmin.cadth.ca/Landing/Register/Register.aspx?Lang=EN) *with the pCODR program. Please visit* [*www.cadth.ca/pcodr/registration*](http://www.cadth.ca/pcodr/registration) *for information about the registration process.*

1. **About the Registered Clinician**

|  |  |
| --- | --- |
| Name of Registered Clinician |  |
| Title |  |
| Disease Specialty (if applicable) |  |
| Province |  |
| Organization Membership (if applicable, national or provincial) |  |
| Email |  |
| Telephone Number |  |

If this is a joint clinician input submission, please indicate the organization this submission is on behalf of, as well as list the names of the other clinicians and disease site specialty (if applicable). Please note that all clinicians listed must also register with CADTH and complete conflict of interest declaration forms.

|  |
| --- |
|  |

**Confirmation of Authorship**

I declare that I am the author of this submission and I confirm that no other parties have written or participated in the writing of the submission, except for those abovenamed in this joint submission (if applicable).

|  |  |  |
| --- | --- | --- |
|  |  |  |
| Signature |  | Date (YYYY/MM/DD) |

1. **About the Drug and Indication Under Review**

|  |  |
| --- | --- |
| CADTH pCODR Project Number | pCODR 10226 |
| Generic Drug Name (Brand Name) | Dabrafenib mesylate (Tafinlar) and Trametinib (Mekinist) |
| Indication | Dabrafenib in combination with trametinib is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation. |
| Funding Request | Dabrafenib in combination with trametinib for the treatment of patients with metastatic NSCLC with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease. |
| Trial(s) Being Submitted to pCODRa | BRF113928 trial ([NCT01336634](https://clinicaltrials.gov/ct2/show/NCT01336634)) |
| Health Canada Status | Approved (05-18-2018) |
| FDA | Approved (06-22-2017) |
| European Medicines Agency Status | Approved (03-29-2017) |
| Practice Guidelinesa | [NCCN](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf) |
| Provincial Funding of Current Treatments or Funding Algorithm | There is no specific first-line therapy for BRAF V600-mutated NSCLC. The standard first line treatment for patients with NSCLC is histology-specific platinum doublet chemotherapy. Pembrolizumab monotherapy is available for patients whose tumours have high (≥50%) PD-L1 expression. For patients with any level of PD-L1 expression, pembrolizumab in combination with chemotherapy is also available. PAG noted that nivolumab-ipilimumab in combination with chemotherapy for first line NSCLC is currently under review at pCODR. In addition, PAG noted that atezolizumab as monotherapy for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations is currently under review at pCODR. Targeted therapies are available for NSCLC with known activating mutations or genetic aberrations in ALK and EGFR genes. |

a Please note that access to some online publications require subscription.

1. **Key Questions for Clinician Input**

## 3.1 Current Treatment(s) for the Indication Under Review:

* If this is different than what is listed in the Provincial Funding of Current Treatments or Funding Algorithm on the previous page, identify the treatment(s) you would use.
* If more than one treatment is funded in your province, identify the treatment(s) that would be the most appropriate comparator for the drug under review.

|  |
| --- |
|  |

## 3.2 Eligible Patient Population

Describe the patients for whom you would use the new treatment. Examples can include, but are not limited to, the following questions:

* Does the patient population in the reimbursement request align with the need identified in your clinical practice? Is there an unmet need?
* Can the inclusion and exclusion criteria of the clinical trial be applied in clinical practice?
* Is there a subgroup of patients beyond the study population that you would like to use the new treatment in? Is there a subgroup of patients within the study population that the new treatment should be limited to?

|  |
| --- |
|  |

## 3.3 Relevance to Clinical Practice

Do you have experience with using the treatment (through clinical trials, manufacturer’s access program, private drug insurance) under review?

Yes No

* How or when would you use the new treatment? Is there any population/subpopulation where you particularly want to use this drug?
* How is the new treatment different than currently available treatments with respect to efficacy, safety, and tolerability?
* Are there contraindications to using the new treatment? Are there contraindications to current treatments that would make the new treatment favourable?

Please note: Scientific published references are not required, as pCODR has access to current scientific literature through the manufacturer’s submission and a rigorous, independent literature search.

|  |
| --- |
|  |

## 3.4 Sequencing and Priority of Treatments

* Please describe how the new treatment could be sequenced with current treatment(s), if appropriate.
* In your opinion, in the event that the drug under review becomes available for funding in your jurisdiction, would the new treatment be a replacement of current treatment(s) or another option?

|  |
| --- |
|  |

**IMPLEMENTATION QUESTIONS**

* **Is there evidence or is it reasonable to continue dabrafenib with trametinib for patients who experience a single or isolated site of disease progression that can be treated "locally" (e.g., a localized treatment modality like RT or RFA)?**

|  |
| --- |
|  |

* **What evidence is there to inform treatment upon progression of dabrafenib and trametinib in patients with BRAF mutation positive NSCLC?**

|  |
| --- |
|  |

* **Does PDL1 status have any influence on the preferred treatment sequence ?**

|  |
| --- |
|  |

## 3.5 Companion Diagnostic Testing

* If companion diagnostic testing is required for the new drug, is the test available in your jurisdiction? Is it funded by your jurisdiction? What concerns, if any, do you have on the test and turnaround time for test results? Are there specific considerations to a testing algorithm that you think would be important to share with the pCODR Expert Review Committee?

|  |
| --- |
|  |

**Appendix A: pCODR Clinician Conflict of Interest Declarations**

**Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.**

|  |  |
| --- | --- |
| **Name of registered clinician:** |  |
| **Name of drug and indication under review:** |  |

**Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

* financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
* affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

**Section A: Payment Received**

1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?

|  |  |
| --- | --- |
|  | Yes |
|  | No |

If no, please go to Section B.

1. What form of payment did you receive? (Check all that apply.)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Advisory role (e.g., advisory boards, health technology assessment submission advice) |  | Program or Operating Funding (e.g., website) |  |
|  | Conference attendance |  | Research/educational grants |  |
|  | Royalties |  | Travel grants |  |
|  | Gifts |  | Sponsorship of events |  |
|  | Honoraria |  | Other, please specify: |  |

1. Please provide the names of companies and organizations, and the amounts of the payments, in the following table.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Company** | **Nature or description of activities or interests** | **Check Appropriate Dollar Range** | | | |
| **$0 to 5,000** | **$5,001 to 10,000** | **$10,001 to 50,000** | **In Excess of $50,000** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

**Section B: Holdings or Other Interests**

Have you received or are in possession of stocks or options of more than $10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

|  |
| --- |
|  |

**Section C: Affiliations, Personal or Commercial Relationships**

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer’s parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

|  |
| --- |
|  |

|  |  |
| --- | --- |
| By checking this box, I hereby certify that the information that I have presented here is accurate and complete to the best of my knowledge. |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
| Date |  | Name |  |